|
|
|
|
||
Re: Tons of huge run ups in biotech recently Big premium buyouts and we sit in low 20s stillJad. So you think there will be over a 25% increase in revenues in 4Q over the 3Q, but only a 16% increase in the 1Q'20 over 4Q'19. Are you assuming they are peaking in scripts and/or not being included in ATS guidelines for NTM? Or, are you just being conservative? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
48869 | Re: Tons of huge run ups in biotech recently Big premium buyouts and we sit in low 20s still | JAD9000 | 3 | 12/11/2019 11:39:25 AM |